247 related articles for article (PubMed ID: 12140383)
1. Frequent downregulation of Fas (CD95) expression and function in melanoma.
Bullani RR; Wehrli P; Viard-Leveugle I; Rimoldi D; Cerottini JC; Saurat JH; Tschopp J; French LE
Melanoma Res; 2002 Jun; 12(3):263-70. PubMed ID: 12140383
[TBL] [Abstract][Full Text] [Related]
2. Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma.
Ugurel S; Seiter S; Rappl G; Stark A; Tilgen W; Reinhold U
Int J Cancer; 1999 Aug; 82(5):727-36. PubMed ID: 10417772
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression.
Mishima K; Nariai Y; Yoshimura Y
Int J Cancer; 2003 Jul; 105(5):593-600. PubMed ID: 12740905
[TBL] [Abstract][Full Text] [Related]
4. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells.
Kirchhoff S; Müller WW; Li-Weber M; Krammer PH
Eur J Immunol; 2000 Oct; 30(10):2765-74. PubMed ID: 11069056
[TBL] [Abstract][Full Text] [Related]
6. Regulation of Fas-mediated apoptosis by N-ras in melanoma.
Urquhart JL; Meech SJ; Marr DG; Shellman YG; Duke RC; Norris DA
J Invest Dermatol; 2002 Sep; 119(3):556-61. PubMed ID: 12230495
[TBL] [Abstract][Full Text] [Related]
7. Expression of the MC1 receptor gene in normal and malignant human melanocytes. A semiquantitative RT-PCR study.
Loir B; Pérez Sánchez C; Ghanem G; Lozano JA; García-Borrón JC; Jiménez-Cervantes C
Cell Mol Biol (Noisy-le-grand); 1999 Nov; 45(7):1083-92. PubMed ID: 10644013
[TBL] [Abstract][Full Text] [Related]
8. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis, Fas and Fas-ligand expression in melanocytic tumors.
Sprecher E; Bergman R; Meilick A; Kerner H; Manov L; Reiter I; Shafer Y; Maor G; Friedman-Birnbaum R
J Cutan Pathol; 1999 Feb; 26(2):72-7. PubMed ID: 10082396
[TBL] [Abstract][Full Text] [Related]
10. Selective expression of FLIP in malignant melanocytic skin lesions.
Bullani RR; Huard B; Viard-Leveugle I; Byers HR; Irmler M; Saurat JH; Tschopp J; French LE
J Invest Dermatol; 2001 Aug; 117(2):360-4. PubMed ID: 11511316
[TBL] [Abstract][Full Text] [Related]
11. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
[TBL] [Abstract][Full Text] [Related]
12. Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes.
Ferrarini M; Imro MA; Sciorati C; Heltai S; Protti MP; Pellicciari C; Rovere P; Manfredi AA; Rugarli C
Int J Cancer; 1999 May; 81(4):573-9. PubMed ID: 10225447
[TBL] [Abstract][Full Text] [Related]
13. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
14. Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release.
Raisova M; Bektas M; Wieder T; Daniel P; Eberle J; Orfanos CE; Geilen CC
FEBS Lett; 2000 May; 473(1):27-32. PubMed ID: 10802053
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation and function of the Fas/Fas ligand system in human trophoblast cells.
Aschkenazi S; Straszewski S; Verwer KM; Foellmer H; Rutherford T; Mor G
Biol Reprod; 2002 Jun; 66(6):1853-61. PubMed ID: 12021072
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD95 ligand in melanocytic lesions as a diagnostic marker.
Maeda A; Aragane Y; Tezuka T
Br J Dermatol; 1998 Aug; 139(2):198-206. PubMed ID: 9767232
[TBL] [Abstract][Full Text] [Related]
17. Production of cytokines by human melanoma cells and melanocytes.
Krüger-Krasagakes S; Krasagakis K; Garbe C; Diamantstein T
Recent Results Cancer Res; 1995; 139():155-68. PubMed ID: 7597287
[TBL] [Abstract][Full Text] [Related]
18. Expression patterns of S100 proteins in melanocytes and melanocytic lesions.
Petersson S; Shubbar E; Enerbäck L; Enerbäck C
Melanoma Res; 2009 Aug; 19(4):215-25. PubMed ID: 19521263
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
[TBL] [Abstract][Full Text] [Related]
20. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
